• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Interview with Harry Peaker

2018-04-25News

What is your current role in EPAD?

As a Data Scientist at Aridhia, I support the development and maintenance of the Analytical Database for the EPAD Longitudinal Cohort Study. IQVIA securely transfer the collated project data from their EDC platform (Medidata Rave) to our digital research platform (AnalytiXagility) on a regular basis. We transform the data into the Health Analytics Schema (HAS), a database model designed by Aridhia to support consistent health analytics. The Analytical Database is then used to support several work packages within the EPAD project such as the Balancing Committee and the disease modelling work.

Aridhia also provide several AnalytiXagility workspaces – cloud-based, private research environments – where EPAD project partners can access the Analytical Database and collaborate around the data. I have been involved in the development of several prototype applications within this environment to support the Balancing Committee in their decision making, help track the recruitment to and growth of the EPAD LCS and provide interactive visualisations of the data in the Analytical Database.

 

What did you do prior to joining EPAD?

I have been at Aridhia now for 4 years. Prior to joining the company, I studied mathematics at the University of Edinburgh and so I really enjoy building modular solutions to address complex problems. I also enjoy diving into the specific analysis, visualisation and modelling tasks expected of a data scientist when the opportunity arises. Although this is often a small part of the battle, especially when healthcare data is involved.

During my time at Aridhia I’ve been involved in many projects including CHART-ADAPT, where Aridhia supported the use of high-frequency data to advance research and treatment for patients with traumatic brain injuries. I’m currently working closely with Great Ormond Street Hospital NHS Foundation Trust and Radboud University Nijmegen Medical Centre, where AnalytiXagility functions as the organisation’s digital research and innovation platform.

 

Tell us a bit about the institution/company/organisation you work for.

Aridhia was founded on the principle that to bring about real change, a multidisciplinary, collaborative and data-driven approach to innovation is vital. Early development of AnalytiXagility was funded by Innovate UK in 2013, and today the platform is commercially available as a fully-fledged collaborative digital research environment for biomedical research, precision medicine and healthcare teams.

We are headquartered in Glasgow’s Queen Elizabeth University Hospital, and from there the Aridhia team delivers open innovation services across the UK and Europe in collaboration with the NHS, research organisations, life sciences companies, IT service providers and patients.

 

What are your expectations from the EPAD project?

EPAD is an extremely innovative and ambitious project both within itself and in its initiative in adopting consistent and reproducible approaches to trial recruitment; integration of multiple data sources; and secure, ethical use and re-use of research data. I am delighted to be involved in the project as recruitment to the adaptive clinical trials begins with great potential for the advancement of our understanding of Alzheimer’s dementia and the development of preventive treatments. I also hope that the lessons learned, and approaches adopted within EPAD can be used to inform clinical trials in other domains, accelerating innovation within healthcare research.

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
The final EPAD dataset is now available to the entire research community
2020-11-30
ALZFORUM
Alzforum conference blog mentions EPAD
2020-11-30
EPAD v1500 dataset
New webpage dedicated to EPAD data and samples on the EPAD website
2020-11-18
ADDI launches new Workbench to foster greater global research innovation and accelerate breakthroughs in Alzheimer’s disease and related dementias
2020-11-17
New paper investigating the prediction of Alzheimer’s disease biomarker status
2020-11-12
The Alzheimer’s Disease Data Initiative supports EPAD
2020-11-06
Latest News
  • The final EPAD dataset is now available to the entire research community
    2020-11-30
  • ALZFORUM
    Alzforum conference blog mentions EPAD
    2020-11-30
  • EPAD v1500 dataset
    New webpage dedicated to EPAD data and samples on the EPAD website
    2020-11-18
  • ADDI launches new Workbench to foster greater global research innovation and accelerate breakthroughs in Alzheimer’s disease and related dementias
    2020-11-17
  • New paper investigating the prediction of Alzheimer’s disease biomarker status
    2020-11-12
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

We would like to thank all our followers! A massive thanks also goes to our research participants & members for all their support! Looking back on the years of the @IMI_EPAD project, here's key pictures took at major events. Have a safe & Happy New Year! youtu.be/FeYsOBOhCeo

reply retweet favorite
8:55 am · 2021-01-18
Twitter
EPAD
EPAD
@IMI_EPAD

The videos from #30AEC are online! Check out the @IMI_EPAD presentations on #data sharing by @rodrigobarnes (@aridhia) & Colin Veal (@uniofleicester). Thanks @IMI2_NEURONET and @AlzheimerEurope for giving us the opportunity to present our work. imi-neuronet.org/2020-virtual… twitter.com/IMI2_NEURONET/…

reply retweet favorite
8:43 am · 2021-01-15
Twitter
EPAD
EPAD
@IMI_EPAD

Authors investigated #data from nine studies, including @IMI_EPAD, comprising a total of 60,004 assessed participants. If you want to explore the #Alzheimer's disease data landscape, visit adata.scai.fraunhofer.de @BirkenbihlC @ApitiusHofmann @ddomingof @Simon_Lovestone @TVB_cloud

reply retweet favorite
7:56 am · 2021-01-11
Twitter
EPAD
EPAD
@IMI_EPAD

Numerous studies have collected #Alzheimer's disease cohort #data sets. @BirkenbihlC and colleagues have evaluated the Alzheimer's disease data landscape from a patient‐level data‐centric perspective. @IMI_EPAD @IMI_EMIF @NACCALZ alz-journals.onlinelibrary.wi…

reply retweet favorite
7:48 am · 2021-01-11
Twitter
EPAD
EPAD
@IMI_EPAD

The final @IMI_EPAD dataset is now available to the entire research community | News | @CORDIS_EU | European Commission europa.eu/!dj89jY

reply retweet favorite
12:55 pm · 2021-01-08
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.